Skip to main content
HROW
NASDAQ Life Sciences

10% Owner Opaleye Management Sells $7.8M in Harrow Stock

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$36.5
Mkt Cap
$1.347B
52W Low
$20.85
52W High
$54.85
52W Position info
75% above low
Off High info
33% below high
Rel. Volume info
3.1× avg
Market data snapshot near publication time

HROW sits 75% above its 52-week low of $20.85 on elevated volume (3.1× avg).

Summary

Opaleye Management Inc., a 10% owner of Harrow, Inc., disposed of approximately $7.8 million worth of common stock in open market sales.


Key Events · Ownership and Investor Activity · HROW

  • 10% Owner Sells Shares

    Opaleye Management Inc., a significant institutional investor and 10% owner of Harrow, Inc., sold 198,572 shares of common stock.

  • Substantial Value Disposed

    The total value of the shares sold was approximately $7.85 million, executed in open market transactions on March 3rd and 4th, 2026.

  • Timing Post-Positive News

    This sale occurred immediately after Harrow, Inc. reported strong Q4 earnings and initiated a Phase 3 clinical trial, potentially signaling a lack of increased conviction despite recent positive developments.


Analysis · HROW · Life Sciences

This Form 4 filing reports a substantial open market sale of Harrow, Inc. common stock by Opaleye Management Inc., a 10% owner. The disposition of approximately $7.85 million in shares, representing 0.583% of the company's market capitalization, indicates a notable reduction in exposure by a significant institutional investor. While such sales by 10% owners can be for portfolio rebalancing, the timing, just days after the company reported strong Q4 earnings and initiated a Phase 3 clinical trial, could be viewed negatively by the market as it suggests a lack of increased conviction despite recent positive operational developments.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, HROW was trading at $36.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $20.85 to $54.85. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

HROW - Latest Insights

HROW
Nov 09, 2026, 5:12 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $31.90
Real-time Price: $30.30 info
Change: -$1.60 (-5%) info
Market Cap: $1.141B info
HROW
Nov 09, 2026, 4:13 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $31.14
Real-time Price: $30.30 info
Change: -$0.843 (-3%) info
Market Cap: $1.141B info
HROW
Nov 09, 2026, 4:02 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $27.44
Real-time Price: $30.30 info
Change: +$2.86 (+10%) info
Market Cap: $1.141B info
HROW
Oct 05, 2026, 7:32 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $30.90
Real-time Price: $30.30 info
Change: -$0.600 (-2%) info
Market Cap: $1.141B info
HROW
Aug 21, 2026, 12:09 PM EDT
Source: Benzinga
Importance Score:
7
Price at Filing: $41.61
Real-time Price: $30.30 info
Change: -$11.31 (-27%) info
Market Cap: $1.141B info